Transdermal Patch Bioequivalence for Long Half-Life Drugs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current transdermal delivery systems fail to achieve pharmacokinetic bioequivalence with oral delivery for therapeutic agents with long half-lives, leading to inconsistent drug levels and increased non-clinical and clinical testing costs.
Innovation Solution
A transdermal delivery system comprising a therapeutic agent with a half-life greater than 48 hours, designed to provide bioequivalent pharmacokinetics to oral administration by using a drug reservoir with specific formulations, such as donepezil or memantine, and a contact adhesive, which includes permeation enhancers like triethyl citrate and lauryl lactate, to maintain consistent plasma levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If transdermal delivery systems are used for therapeutic agents with long half-lives, then sustained plasma levels can be maintained, but pharmacokinetic bioequivalence with oral delivery cannot be achieved
Solution Approach 1:
The patent changes the formulation parameters of the transdermal system by incorporating specific permeation enhancers (triethyl citrate, lauryl lactate) and reservoir formulations to modify drug release characteristics. This allows the transdermal system to achieve pharmacokinetic profiles (AUC and Cmax) that are bioequivalent to oral delivery while maintaining sustained plasma levels.
Solution Approach 2:
The patent uses composite formulation materials including permeation enhancers (triethyl citrate, lauryl lactate), reservoir matrices, and adhesive components to create a transdermal delivery system that simultaneously achieves sustained release and bioequivalent pharmacokinetics. The composite nature of the formulation enables both steady-state maintenance and peak concentration achievement.
2Duration of action of moving object
If transdermal delivery systems are designed for long half-life drugs, then sustained release can be achieved, but consistent plasma levels with oral bioequivalence are not obtained
Solution Approach 1:
The patent employs periodic dosing regimens (daily or weekly application) where the transdermal system is applied for a specific duration to achieve steady-state plasma levels, then removed and reapplied. This periodic action pattern, combined with the reservoir formulation, enables both sustained release over the wear period and bioequivalent pharmacokinetics when compared to oral dosing intervals.
Solution Approach 2:
The patent creates a dynamic delivery system where the reservoir formulation adjusts drug release rates based on skin permeation conditions and maintains plasma levels within the therapeutic range. The system transitions from initial application through steady-state achievement to removal, with each phase controlled by the formulation dynamics to achieve oral bioequivalence.
3Duration of action of stationary object
If conventional transdermal systems are used, then sustained release is achieved, but extensive non-clinical and clinical testing costs are incurred due to lack of bioequivalence
Solution Approach 1:
The patent creates a transdermal delivery system that copies the pharmacokinetic profile of oral delivery (achieving bioequivalence in AUC and Cmax), thereby allowing results from oral bioequivalence studies to be applicable to the transdermal formulation. This eliminates the need for extensive separate non-clinical and clinical testing that would otherwise be required to establish safety and efficacy for the transdermal route.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system achieves bioequivalence in terms of Cmax and AUC, reducing testing costs and maintaining consistent therapeutic levels, as demonstrated by studies showing comparable plasma concentrations to oral administration.
Implementation Method 1
a contact adhesive, which includes permeation enhancers like triethyl citrate and lauryl lactate, to maintain consistent plasma levels
Implementation Method 2
a drug reservoir with controlled-release formulations
Data Source
AI summary
A method for delivering a therapeutic agent to a subject from a transdermal delivery system is described, where the therapeutic agent (i) has a half-life in the blood when delivered orally of greater than about 48 hours and (ii) is for the treatment of a chronic condition. The transdermal delivery system achieves transdermal delivery of the therapeutic agent that is bioequivalent to administration of the therapeutic agent orally, wherein bioequivalency is established by (a) a 90% confidence interval of the relative mean Cmax and AUC of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25, or (b) a 90% confidence interval of the geometric mean ratios for AUC and Cmax of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25.